Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer

Radiation Oncology

Patrick Cheung⁴  Jean-Philippe Pignol⁴  Cyril Danjoux⁴  Ewa Szumacher²  Richard Choo¹  Gerard Morton⁴  Kelvin Chan³  D Andrew Loblaw⁴  William Chu⁴ 

[1] Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA;Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Ave., Toronto M4N 3 M5, ON, Canada;Department of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada;Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada

关键词: Toxicity;    Prostate cancer;    Intensity modulated radiotherapy;    Image-guided radiotherapy;    Hypofractionation;    Biochemical outcomes;   

Others  :  1177381
DOI  :  10.1186/s13014-015-0400-1

 received in 2014-05-13, accepted in 2015-04-02,  发布年份 2015

【 摘 要 】

Background

This is the final report of a prospective phase I study which evaluated the feasibility, toxicities, and biochemical control in prostate cancer patients treated with a hypofractionated boost utilizing a fiducial marker-based daily image guidance strategy and small patient-specific PTV margins.

Methods

Low- and intermediate-risk prostate cancer patients underwent transperineal ultrasound-guided implantation of three gold fiducial markers and were treated with three-dimensional conformal radiotherapy to 42 Gy (2 Gy/day). During the first nine fractions of treatment, pre- and post-treatment electronic portal imaging was performed to calculate intrafraction prostate motion. Patient-specific PTV margins were derived and a 30 Gy (3 Gy/day) intensity modulated radiotherapy boost was delivered (Total dose = 72 Gy in 31 fractions; EQD2 = 81 Gy, α/β = 1.4).

Results

Thirty-three patients completed treatment and were followed for a median of 7.2 years (range, 1.2 – 9.5). Seven patients (21%) developed Radiation Therapy Oncology Group (RTOG) late grade 2 GI toxicity and 1 patient (3%) developed late grade 2 GU toxicity. No patients developed late grade 3 GI or GU toxicity. To date, nine patients developed PSA relapse according to the Phoenix criteria. The actuarial five, seven and nine year biochemical control (BC) rates were 87% (95% confidence interval: 69–95), 77% (95% confidence interval: 56–89) and 66% (95% confidence interval: 42–82).

Conclusions

Our study demonstrates that the use of prostate fiducial markers in combination with a daily online image guidance protocol permits reduced, patient-specific PTV margins in a hypofractionated treatment scheme. This treatment planning and delivery strategy was well tolerated in the intermediate time frame. The use of very small PTV margins did not result in excessive failures when compared to other radiation regimens of similar radiobiological intensity.

【 授权许可】

   
2015 Chu et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR et al.. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70(1):67-74.
• [2]Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW et al.. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005; 61(4):1019-34.
• [3]Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF et al.. Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006; 24(13):1990-6.
• [4]Al-Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Dielwart MF et al.. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 72(4):980-8.
• [5]Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA et al.. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005; 294(10):1233-9.
• [6]Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ et al.. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95–09. J Clin Oncol. 2010; 28(7):1106-11.
• [7]Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA et al.. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007; 8(6):475-87.
• [8]Syndikus I, Morgan RC, Sydes MR, Graham JD, Dearnaley DP. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys. 2010; 77(3):773-83.
• [9]Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, Chauvet B et al.. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011; 80(4):1056-63.
• [10]Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys. 2009; 74(5):1405-18.
• [11]Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002; 52(1):6-13.
• [12]Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001; 50(4):1021-31.
• [13]Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys. 2012; 82(1):e17-24.
• [14]Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999; 43(5):1095-101.
• [15]Daşu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol). 2007; 19(5):289-301.
• [16]Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Time-dose factors in radiotherapy: a review of the human data. Radiol Oncol. 1990; 19(3):219-35.
• [17]Sethukavalan P, Cheung P, Tang CI, Quon H, Morton G, Nam R et al.. Patient costs associated with external beam radiotherapy treatment for localized prostate cancer: the benefits of hypofractionated over conventionally fractionated radiotherapy. Can J Urol. 2012; 19(2):6165-9.
• [18]Aubry JF, Beaulieu L, Girouard LM, Aubin S, Tremblay D, Laverdière J et al.. Measurements of intrafraction motion and interfraction and intrafraction rotation of prostate by three-dimensional analysis of daily portal imaging with radiopaque markers. Int J Radiat Oncol Biol Phys. 2004; 60(1):30-9.
• [19]Ghilezan MJ, Jaffray DA, Siewerdsen JH, Van Herk M, Shetty A, Sharpe MB et al.. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int J Radiat Oncol Biol Phys. 2005; 62(2):406-17.
• [20]Kupelian P, Willoughby T, Mahadevan A, Djemil T, Weinstein G, Jani S et al.. Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 67(4):1088-98.
• [21]Cheung P, Sixel K, Morton G, Loblaw DA, Tirona R, Pang G et al.. Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer. Int J Radiat Oncol Biol Phys. 2005; 62(2):418-25.
• [22]Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol. 2001; 8(4):1314-22.
• [23]Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997; 80(9):1803-4.
• [24]Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31(5):1341-6.
• [25]Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH et al.. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65(4):965-74.
• [26]Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC et al.. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001; 166(3):876-81.
• [27]Kaplan E, Meier P. Nonparametric estimation from incompete observations. J Am Stat Assoc. 1958; 53:457-81.
• [28]Kotte AN, Hofman P, Lagendijk JJ, van Vulpen M, van der Heide UA. Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys. 2007; 69(2):419-25.
• [29]Middleton M, See A, Rolfo A, Medwell S, Joon ML, Joon DL et al.. Intraprostatic fiducials for image guidance: Workflow implications in a single linac department. Radiography. 2008; 14(4):312-7.
• [30]Oehler C, Lang S, Dimmerling P, Bolesch C, Kloeck S, Tini A et al.. PTV margin definition in hypofractionated IGRT of localized prostate cancer using cone beam CT and orthogonal image pairs with fiducial markers. Radiat Oncol. 2014; 9(1):229. BioMed Central Full Text
• [31]Viani GA, da Silva LG, Stefano EJ. High-dose conformal radiotherapy reduces prostate cancer-specific mortality: results of a meta-analysis. Int J Radiat Oncol Biol Phys. 2012; 83(5):e619-25.
• [32]Arcangeli G, Fowler J, Gomellini S, Arcangeli S, Saracino B, Petrongari MG et al.. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011; 79(4):1013-21.
• [33]Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C et al.. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. 2012; 13(1):43-54.
• [34]Kuban DA, Nogueras-Gonzalez GM, Hamblin L, Lee AK, Choi S, Frank SJ et al.. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys. 2010; 78(3):S58-9.
• [35]Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Konski AA, Movsas B et al.. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys. 2006; 64(2):518-26.
• [36]Pollack A, Walker G, Buyyounouski M, Horwitz E, Price R, Feigenberg S et al.. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2011; 81(2):S1.
• [37]Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnaro P et al.. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 84(5):1172-8.
• [38]Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S et al.. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010; 78(1):11-8.
• [39]Hegemann NS, Guckenberger M, Belka C, Ganswindt U, Manapov F, Li M. Hypofractionated radiotherapy for prostate cancer. Radiat Oncol. 2014; 9(1):275. BioMed Central Full Text
• [40]Taira AV, Merrick GS, Galbreath RW, Butler WM, Lief J, Adamovich E et al.. Distant metastases following permanent interstitial brachytherapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 82(2):e225-32.
• [41]Ghadjar P, Oesch SL, Rentsch CA, Isaak B, Cihoric N, Manser P et al.. Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer. Radiat Oncol. 2014; 9:122. BioMed Central Full Text
• [42]King CR, Brooks JD, Gill H, Presti JC. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 82(2):877-82.
• [43]Loblaw A, Cheung P, D'Alimonte L, Deabreu A, Mamedov A, Zhang L et al.. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes. Radiother Oncol. 2013; 107(2):153-8.
• [44]Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007; 67(4):1099-105.
• [45]Ritter M, Forman J, Kupelian P, Lawton C, Petereit D. Hypofractionation for prostate cancer. Cancer J. 2009; 15(1):1-6.
• [46]Tang CI, Loblaw DA, Cheung P, Holden L, Morton G, Basran PS et al.. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin Oncol (R Coll Radiol). 2008; 20(10):729-37.
• [47]Meier R, Cotrutz C, Loiselle C, Sima S, Vermeulen S. Long-term outcomes of stereotactic body radiation therapy for organ-confined prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 84(3):S417.